
DURECT Investor Relations Material
Latest events

Q4 2024
DURECT
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from DURECT Corp
Access all reports
DURECT Corp is a biopharmaceutical company engaged in the development of therapies using epigenetic modulation for the treatment of acute organ injury and chronic liver diseases. Its research focuses on new chemical entities, with a significant emphasis on its endogenous epigenetic regulator program. The company's pipeline includes products such as DUR-928, aimed at conditions like alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, designed for post-operative pain management; and Oradur, for chronic pain and attention deficit hyperactivity disorders. Additionally, DURECT manufactures and markets osmotic pumps for laboratory research and provides biodegradable polymers and excipients for the pharmaceutical and medical device industries. The company is headquartered in Cupertino, California, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
DRRX
Country
🇺🇸 United States